Physician profile
Sadhana Kumar
NPI 1225065634
$5,415.50
in general payments reported to CMS, 2019-2025
17 companies · $89.73 in 2025
The $89.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $415 · 2021: $1,412 · 2022: $1,248 · 2023: $777 · 2024: $954 · 2025: $89.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Consulting Fee: $350 · Education: $44.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.70 |
| Consulting Fee | $350.00 |
| Education | $44.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,816.95 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $685.17 | 2021-2025 | |
| Novo Nordisk INC | $603.93 | 2019-2023 | Ozempic |
| Lilly USA, LLC | $541.72 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.51 | 2019-2023 | Jardiance |
| Abbvie INC. | $350.00 | 2024 | |
| Vifor Pharma, INC. | $279.01 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $197.08 | 2021-2024 | Jynarque |
| Amarin Pharma, INC. | $156.75 | 2019 | |
| Intuity Medical INC | $104.14 | 2022 | |
| Merck Sharp & Dohme LLC | $92.60 | 2020-2021 | |
| Pfizer INC. | $68.61 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $37.50 | 2020 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Ferring Pharmaceuticals INC. | $18.46 | 2023 | Rebyota |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $14.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadhana Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.